Bexion Pharmaceuticals, Inc. to Present at Biotech Showcase 2024
Company now enrolling a Phase 1b/2 study in 1st Line mCRC and a PK/PD study in CIPN
Presentation Details:
Date:
Time:
Location:
Track: Franciscan A (Ballroom Level)
About Bexion Pharmaceuticals
Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion currently has three clinical trials open and actively enrolling, including a Phase 1b/2 study (in expansion portion) of BXQ-350 in combination with Standard-of-Care for the treatment of 1st Line mCRC and a PK/PD study of BXQ-350 for the treatment of patients with CIPN.
Investor Contact:
Solebury Strategic Communications
646-378-2946
[email protected]
Media Contact:
Bexion Pharmaceuticals
859-446-7386
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-to-present-at-biotech-showcase-2024-302026963.html
SOURCE Bexion Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KANEKA UBIQUINOL™ WINS NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026
- Lyntris Completes CDR for KSAT Hyperion Satellite Program
- Global Semiconductor Equipment Billings Increased 23% Year-Over-Year in Q2 2026, SEMI Reports
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share